Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase...

por Bressler, Neil M., Kim, Taehyung, Oh, Inkyung, Russo, Paola, Kim, Mercy Yeeun, Woo, Se Joon
Publicado 2022

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

por Bressler, Neil M, Veith, Miroslav, Hamouz, Jan, Ernest, Jan, Zalewski, Dominik, Studnička, Jan, Vajas, Attila, Papp, András, Vogt, Gabor, Luu, James, Matuskova, Veronika, Yoon, Young Hee, Pregun, Tamás, Kim, Taehyung, Shin, Donghoon, Oh, Inkyung, Jeong, Hansol, Kim, Mercy Yeeun, Woo, Se Joon
Publicado 2023